Testing effectiveness (Phase 2)Study completedNCT02089685
What this trial is testing
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Who this might be right for
Renal Cell CarcinomaMelanoma
Merck Sharp & Dohme LLC 295